Marizyme, Inc. (MRZM)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -65.34 Million USD | -5.1% |
| 2022 | -62.17 Million USD | -538.57% |
| 2021 | -9.73 Million USD | -65.3% |
| 2020 | -5.89 Million USD | -456.74% |
| 2019 | -1.05 Million USD | -325.35% |
| 2018 | -248.74 Thousand USD | 56.4% |
| 2017 | -570.5 Thousand USD | 34.63% |
| 2016 | -872.71 Thousand USD | 90.35% |
| 2015 | -9.04 Million USD | 11.6% |
| 2014 | -10.23 Million USD | -321.23% |
| 2013 | -2.42 Million USD | 31.72% |
| 2012 | -3.55 Million USD | -95.78% |
| 2011 | -1.81 Million USD | -10009.49% |
| 2010 | -17.98 Thousand USD | 6.65% |
| 2009 | -19.26 Thousand USD | 80.28% |
| 2008 | -97.66 Thousand USD | -283.96% |
| 2007 | -25.43 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.07 Million USD | 34.59% |
| 2024 Q1 | -6.22 Million USD | 36.24% |
| 2023 Q2 | -20.57 Million USD | -336.56% |
| 2023 Q3 | -32.45 Million USD | -57.71% |
| 2023 Q4 | -9.76 Million USD | 69.91% |
| 2023 Q1 | -4.71 Million USD | 89.52% |
| 2023 FY | -65.34 Million USD | -5.1% |
| 2022 FY | -62.17 Million USD | -538.57% |
| 2022 Q2 | -9.24 Million USD | -12.02% |
| 2022 Q1 | -8.25 Million USD | -49.67% |
| 2022 Q3 | -872.23 Thousand USD | 90.57% |
| 2022 Q4 | -44.98 Million USD | -5057.44% |
| 2021 Q4 | -5.51 Million USD | -237.94% |
| 2021 FY | -9.73 Million USD | -65.3% |
| 2021 Q1 | -2.81 Million USD | 2.2% |
| 2021 Q2 | -2.46 Million USD | 12.44% |
| 2021 Q3 | -1.63 Million USD | 33.68% |
| 2020 Q1 | -471.37 Thousand USD | -93.58% |
| 2020 Q4 | -2.87 Million USD | -39.16% |
| 2020 Q3 | -2.06 Million USD | -374.82% |
| 2020 Q2 | -434.91 Thousand USD | 7.73% |
| 2020 FY | -5.89 Million USD | -456.74% |
| 2019 FY | -1.05 Million USD | -325.35% |
| 2019 Q4 | -243.49 Thousand USD | 52.12% |
| 2019 Q1 | -67.54 Thousand USD | -8.93% |
| 2019 Q2 | -237.36 Thousand USD | -251.41% |
| 2019 Q3 | -508.56 Thousand USD | -114.26% |
| 2018 Q3 | -72.81 Thousand USD | -10.42% |
| 2018 Q1 | -47.97 Thousand USD | 92.47% |
| 2018 FY | -248.74 Thousand USD | 56.4% |
| 2018 Q4 | -62.01 Thousand USD | 14.84% |
| 2018 Q2 | -65.94 Thousand USD | -37.47% |
| 2017 FY | -570.5 Thousand USD | 34.63% |
| 2017 Q3 | 39.57 Thousand USD | 428.21% |
| 2017 Q4 | -636.84 Thousand USD | -1709.05% |
| 2017 Q2 | 7493.00 USD | -44.0% |
| 2017 Q1 | 13.38 Thousand USD | 100.91% |
| 2016 FY | -872.71 Thousand USD | 90.35% |
| 2016 Q4 | -1.47 Million USD | -5000.0% |
| 2016 Q1 | -100 Thousand USD | 0.0% |
| 2016 Q3 | 30 Thousand USD | 250.0% |
| 2016 Q2 | -20 Thousand USD | 80.0% |
| 2015 FY | -9.04 Million USD | 11.6% |
| 2014 FY | -10.23 Million USD | -321.23% |
| 2013 Q3 | -1.13 Million USD | -469.38% |
| 2013 Q2 | -199.84 Thousand USD | 85.02% |
| 2013 Q1 | -1.33 Million USD | -512.51% |
| 2013 Q4 | 241.85 Thousand USD | 121.26% |
| 2013 FY | -2.42 Million USD | 31.72% |
| 2012 Q3 | -442.38 Thousand USD | 53.52% |
| 2012 FY | -3.55 Million USD | -95.78% |
| 2012 Q4 | -217.81 Thousand USD | 50.76% |
| 2012 Q2 | -951.77 Thousand USD | 90.56% |
| 2012 Q1 | -10.08 Million USD | -1013.09% |
| 2011 Q2 | -1.81 Million USD | -12.92% |
| 2011 Q1 | -1.6 Million USD | -716.22% |
| 2011 Q3 | -1.89 Million USD | -4.3% |
| 2011 FY | -1.81 Million USD | -10009.49% |
| 2011 Q4 | -905.78 Thousand USD | 52.15% |
| 2010 Q1 | -2079.00 USD | -126.22% |
| 2010 FY | -17.98 Thousand USD | 6.65% |
| 2010 Q4 | -196.91 Thousand USD | -1119.28% |
| 2010 Q3 | -16.15 Thousand USD | -232.29% |
| 2010 Q2 | 12.2 Thousand USD | 687.21% |
| 2009 FY | -19.26 Thousand USD | 80.28% |
| 2009 Q1 | 15.44 Thousand USD | 353.05% |
| 2009 Q2 | -6128.00 USD | -139.67% |
| 2009 Q4 | -919.00 USD | 97.12% |
| 2009 Q3 | -31.92 Thousand USD | -420.97% |
| 2008 Q4 | -6104.00 USD | 70.93% |
| 2008 FY | -97.66 Thousand USD | -283.96% |
| 2008 Q1 | -27.34 Thousand USD | 3.58% |
| 2008 Q2 | -13.73 Thousand USD | 49.78% |
| 2008 Q3 | -20.99 Thousand USD | -52.89% |
| 2007 Q4 | -28.35 Thousand USD | -42.37% |
| 2007 Q1 | -10 Thousand USD | 0.0% |
| 2007 FY | -25.43 Thousand USD | 0.0% |
| 2007 Q2 | -21.62 Thousand USD | -116.27% |
| 2007 Q3 | -19.91 Thousand USD | 7.9% |
| 2006 Q4 | -10 Thousand USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -4793.32% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -835.822% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 223.345% |
| Nascent Biotech, Inc. | -2.08 Million USD | -3030.118% |
| Rebus Holdings, Inc. | -1.02 Million USD | -6306.56% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 200.329% |
| Qrons Inc. | -789.34 Thousand USD | -8178.604% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -10233.047% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -4.39% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -15628.091% |
| Skye Bioscience, Inc. | -37.64 Million USD | -73.588% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 12.828% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -893.702% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -23801.403% |
| SQZ Biotechnologies Company | -79.46 Million USD | 17.765% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -2159.267% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -3489.449% |
| Mesoblast Limited | -87.95 Million USD | 25.705% |
| Genus plc | 7.9 Million USD | 927.176% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -499.968% |
| Pharming Group N.V. | -10.54 Million USD | -519.519% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -2911.637% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -1661.261% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -638.884% |
| ContraFect Corporation | -65.15 Million USD | -0.298% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -1237.414% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -3682.843% |
| IMV Inc. | -36.48 Million USD | -79.103% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -710.788% |
| MultiCell Technologies, Inc. | -380.07 USD | -17193289.376% |
| ONE Bio Corp. | 8.67 Million USD | 853.139% |
| Accustem Sciences Inc. | -3.74 Million USD | -1644.25% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -26.416% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -5057.064% |
| Q BioMed Inc. | -2.05 Million USD | -3084.403% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -1650.52% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -2644.665% |
| Biomind Labs Inc. | -1.21 Million USD | -5281.363% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -9.412% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -2006.763% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -726.852% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -3252.415% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -436244.251% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -311.726% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -1023.329% |
| GB Sciences, Inc. | -1.36 Million USD | -4699.003% |
| Alpha Cognition Inc. | -13.77 Million USD | -374.472% |
| HST Global, Inc. | -146.21 Thousand USD | -44593.875% |
| CSL Limited | 2.64 Billion USD | 102.473% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -3623.957% |
| Halberd Corporation | -79.67 Thousand USD | -81915.808% |
| Enzolytics Inc. | -2.17 Million USD | -2901.927% |
| Agentix Corp. | -1.37 Million USD | -4655.232% |
| Resverlogix Corp. | -3.61 Million USD | -1710.164% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -1960.483% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 77.852% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 66780.526% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 1043.693% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -1544.778% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -2059.418% |
| AVAX Technologies, Inc. | -6.41 Million USD | -918.873% |
| Zenith Capital Corp. | -10.59 Million USD | -516.713% |
| Genscript Biotech Corporation | -95.47 Million USD | 31.557% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -281058.743% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -1476.168% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -108017.564% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -3159.011% |
| Kadimastem Ltd | -3.3 Million USD | -1875.78% |
| Helix BioMedix, Inc. | -1.05 Million USD | -6087.821% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -1611.1% |
| BioStem Technologies, Inc. | -8.48 Million USD | -670.329% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -14705.506% |
| LadRx Corporation | 400.44 Thousand USD | 16418.656% |
| Cell Source, Inc. | -5.32 Million USD | -1128.046% |
| Regen BioPharma, Inc. | 1.02 Million USD | 6484.602% |
| Regen BioPharma, Inc. | 1.02 Million USD | 6484.602% |
| NovAccess Global Inc. | -4.76 Million USD | -1270.19% |
| Affymax, Inc. | -14.42 Million USD | -353.043% |
| Itoco Inc. | -1.86 Million USD | -3396.366% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -1370.938% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -3815.333% |
| Mobile Lads Corp. | -2.26 Million USD | -2787.251% |
| CytoDyn Inc. | -49.84 Million USD | -31.111% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -82583.075% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -28544.972% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -6840.51% |
| SYBLEU INC | -180.3 Thousand USD | -36142.632% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -3951.926% |
| International Stem Cell Corporation | -131 Thousand USD | -49783.141% |
| Bioxytran, Inc. | -4.28 Million USD | -1426.796% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -120306.314% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -2482.63% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -35.936% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -2991.15% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -8268.293% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -1962.718% |
| Neutra Corp. | -233.46 Thousand USD | -27890.026% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -222.049% |
| PureTech Health plc | -65.69 Million USD | 0.533% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -207.276% |
| IXICO plc | -1.17 Million USD | -5447.276% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -558.275% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -14.387% |
| CSL Limited | 2.64 Billion USD | 102.473% |
| Cellectis S.A. | -103.17 Million USD | 36.663% |